Dr Daniel Krell qualified in medicine at Leeds University Medical School, where he also gained a Bachelor’s degree in immunology and microbiology. He completed his junior doctor training at Leeds General infirmary in Leeds and at Guys and St. Thomas’ Hospitals and University College Hospital in London before undertaking his oncology training at The Royal Free and University College Hospitals in London.

Dr Krell’s DPhil research was undertaken at The University of Oxford, Wellcome Trust Centre for Human Genetics, and was funded by Cancer Research UK and HCA. Dr Krell’s research investigated the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer, with a view to identifying new therapeutic targets in this area. He continues to be involved in clinical research and clinical trials aimed at identifying new cancer therapies, with a focus on gastrointestinal and hepatobiliary malignancies.
Dr Krell has published in several peer-reviewed papers in journals such as the British Journal of Cancer and Lancet Oncology, and has submitted and presented abstracts and posters at national and international conferences.

His clinical work focuses on the management of patients with gastro-oesophageal, colorectal, pancreatic, liver and biliary tract cancers using chemotherapy, targeted therapy and immunotherapies. He also manages patients with cancer of unknown primary and is the clinical lead at Barnet hospital for this. He also acts as the MDT lead for gastro-oesophageal and hepatobiliary cancer at his institution. He is also a member of the London cancer expert reference group for acute oncology and cancer of unknown primary.